science
New drug targets pancreatic cancer mutation, significantly improving survival rates
4 Haziran 2026Science Daily
- A groundbreaking development in the fight against pancreatic cancer has emerged with the introduction of daraxonrasib, a drug that targets the KRAS mutation responsible for many pancreatic tumors. This advancement comes after decades of the disease being labeled as 'undruggable.' In a significant clinical trial, the…
- Pancreatic cancer has historically been one of the deadliest forms of cancer, with limited treatment options available. The KRAS mutation has been a significant challenge for researchers, often deemed 'undruggable.' The development of daraxonrasib marks a significant milestone in cancer research, indicating that pre…
- The successful targeting of the KRAS mutation represents a pivotal moment in oncology, particularly for pancreatic cancer, which has long been associated with poor prognoses. This breakthrough not only enhances survival rates but also opens avenues for further research into similar 'undruggable' targets in other mal…
NewsAI özeti
This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional for medical concerns.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.